BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 31867596)

  • 41. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
    Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
    Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Sakhdari A; Tang Z; Ok CY; Bueso-Ramos CE; Medeiros LJ; Huh YO
    Cancer Genet; 2019 Oct; 238():18-22. PubMed ID: 31425921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia.
    Wang H; Lindsey S; Konieczna I; Bei L; Horvath E; Huang W; Saberwal G; Eklund EA
    J Biol Chem; 2009 Jan; 284(4):2549-67. PubMed ID: 19022774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HoxA10 activates CDX4 transcription and Cdx4 activates HOXA10 transcription in myeloid cells.
    Bei L; Huang W; Wang H; Shah C; Horvath E; Eklund E
    J Biol Chem; 2011 May; 286(21):19047-64. PubMed ID: 21471217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization.
    Popovic R; Riesbeck LE; Velu CS; Chaubey A; Zhang J; Achille NJ; Erfurth FE; Eaton K; Lu J; Grimes HL; Chen J; Rowley JD; Zeleznik-Le NJ
    Blood; 2009 Apr; 113(14):3314-22. PubMed ID: 19188669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
    Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
    Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1.
    Wang H; Bei L; Shah CA; Horvath E; Eklund EA
    J Biol Chem; 2011 May; 286(19):16832-45. PubMed ID: 21454682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
    Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
    Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
    Chen X; Clark J; Wunderlich M; Fan C; Davis A; Chen S; Guan JL; Mulloy JC; Kumar A; Zheng Y
    Autophagy; 2017 May; 13(5):955-966. PubMed ID: 28282266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
    Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
    Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
    [No Abstract]   [Full Text] [Related]  

  • 52. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
    Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
    Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
    Krivtsov AV; Figueroa ME; Sinha AU; Stubbs MC; Feng Z; Valk PJ; Delwel R; Döhner K; Bullinger L; Kung AL; Melnick AM; Armstrong SA
    Leukemia; 2013 Apr; 27(4):852-60. PubMed ID: 23235717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
    Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
    Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
    Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
    Wang Z; Shi Y; Liu H; Liang Z; Zhu Q; Wang L; Tang B; Miao S; Ma N; Cen X; Ren H; Dong Y
    Hematol Oncol; 2019 Dec; 37(5):617-625. PubMed ID: 31701557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
    Stubbs MC; Krivtsov AV
    Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-101 suppresses the development of
    Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
    Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
    [No Abstract]   [Full Text] [Related]  

  • 60. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.